LiCABEDS II. Modeling of Ligand Selectivity for G-Protein-Coupled Cannabinoid Receptors

The cannabinoid receptor subtype 2 (CB2) is a promising therapeutic target for blood cancer, pain relief, osteoporosis, and immune system disease. The recent withdrawal of Rimonabant, which targets another closely related cannabinoid receptor (CB1), accentuates the importance of selectivity for the development of CB2 ligands in order to minimize their effects on the CB1 receptor. In our previous study, LiCABEDS (Ligand Classifier of Adaptively Boosting Ensemble Decision Stumps) was reported as a generic ligand classification algorithm for the prediction of categorical molecular properties. Here, we report extension of the application of LiCABEDS to the modeling of cannabinoid ligand selectivity with molecular fingerprints as descriptors. The performance of LiCABEDS was systematically compared with another popular classification algorithm, support vector machine (SVM), according to prediction precision and recall rate. In addition, the examination of LiCABEDS models revealed the difference in structure diversity of CB1 and CB2 selective ligands. The structure determination from data mining could be useful for the design of novel cannabinoid lead compounds. More importantly, the potential of LiCABEDS was demonstrated through successful identification of newly synthesized CB2 selective compounds.

[1]  Andreas Bender,et al.  Molecular Similarity Searching Using Atom Environments, Information-Based Feature Selection, and a Naïve Bayesian Classifier , 2004, J. Chem. Inf. Model..

[2]  B. Frenkel,et al.  Peripheral cannabinoid receptor, CB2, regulates bone mass. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Spring.  Chemical Genetics to Chemical Genomics: Small Molecules Offer Big Insights , 2005 .

[4]  Chih-Jen Lin,et al.  LIBSVM: A library for support vector machines , 2011, TIST.

[5]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[6]  J. Arrowsmith.  Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[7]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[8]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[9]  Yoav Freund,et al.  A decision-theoretic generalization of on-line learning and an application to boosting , 1995, EuroCOLT.

[10]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[11]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[12]  Chen Yan,et al.  GPCR kinase 2 interacting protein 1 (GIT1) regulates osteoclast function and bone mass , 2010, Journal of cellular physiology.

[13]  Chao Ma,et al.  Linear and Nonlinear Support Vector Machine for the Classification of Human 5‐HT1A Ligand Functionality , 2012, Molecular informatics.

[14]  John C Ashton,et al.  Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. , 2008, Current medicinal chemistry.

[15]  J. DiMasi.  The Value of Improving the Productivity of the Drug Development Process , 2012, PharmacoEconomics.

[16]  Michael T. Fisher,et al.  Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. , 2002, Blood.

[17]  Xiang-Qun Xie,et al.  3D structural model of the G‐protein‐coupled cannabinoid CB2 receptor , 2003, Proteins.

[18]  H H Seltzman,et al.  Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs. , 1997, Journal of medicinal chemistry.

[19]  Chao Ma,et al.  Ligand Classifier of Adaptively Boosting Ensemble Decision Stumps (LiCABEDS) and Its Application on Modeling Ligand Functionality for 5HT-Subtype GPCR Families , 2011, J. Chem. Inf. Model..

[20]  Xiang-Qun Xie,et al.  Alkylamides from Echinacea Are a New Class of Cannabinomimetics , 2006, Journal of Biological Chemistry.

[21]  Robin Christensen,et al.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.

[22]  Qin Tong,et al.  Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. , 2012, Journal of medicinal chemistry.

[23]  Xiang-Qun Xie,et al.  Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. , 2012, Future medicinal chemistry.

[24]  Robert Williams,et al.  Chemical genetics and genomics and drug discovery. Highlights from the Society for Medicines Research symposium held Thursday March 10, 2005, in London, United Kingdom. , 2005, Drug news & perspectives.

[25]  Andreas Bender,et al.  Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..

[26]  J. Arrowsmith.  Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[27]  K. Mackie,et al.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. , 1995, Molecular pharmacology.

[28]  J W Huffman,et al.  The search for selective ligands for the CB2 receptor. , 2000, Current pharmaceutical design.

[29]  Anne Mai Wassermann,et al.  Searching for Target-Selective Compounds Using Different Combinations of Multiclass Support Vector Machine Ranking Methods, Kernel Functions, and Fingerprint Descriptors , 2009, J. Chem. Inf. Model..

[30]  Yoav Freund,et al.  A decision-theoretic generalization of on-line learning and an application to boosting , 1997, EuroCOLT.

[31]  Junmei Wang,et al.  GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..

[32]  M. García-Arencibia,et al.  Role of CB2 receptors in neuroprotective effects of cannabinoids , 2008, Molecular and Cellular Endocrinology.